14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AURA vs TRDA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Aura Biosciences, Inc. (AURA) is the stronger overall head-to-head candidate over Entrada Therapeutics, Inc. (TRDA) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AURA carries a Unified Composite Score of 31.1/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas TRDA carries 42.0/100 (HOLD) at $5.06 (N/M Forward P/E, -4256.1% operating margin).
Composite vs. Pillar Nuance: While TRDA currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. AURA 31.1/100 SELL), AURA captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4256.1% operating margin) and revenue trajectory (+0.0% vs. -43.9% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AURA vs TRDA. Trailing 12-month operating profitability (AURA 0.0% vs TRDA -4256.1%) and valuation multiples (AURA N/M vs TRDA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $200.8M market capitalization and -4256.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AURA vs TRDA Key Questions & Quantitative Answers
As of Nov 16, 2026, Aura Biosciences, Inc. (AURA) is the stronger overall head-to-head candidate over Entrada Therapeutics, Inc. (TRDA) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AURA carries a Unified Composite Score of 31.1/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas TRDA carries 42.0/100 (HOLD) at $5.06 (N/M Forward P/E, -4256.1% operating margin). Composite vs. Pillar Nuance: While TRDA currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. AURA 31.1/100 SELL), AURA captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4256.1% operating margin) and revenue trajectory (+0.0% vs. -43.9% YoY).
AURA leads the Growth & Scale pillar: AURA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TRDA at -43.9% YoY revenue growth and +0.0% YoY earnings growth on $4.0M TTM revenue (N/A gross margin, -4256.1% operating margin). On trailing 12-month operating scale, AURA generates N/A in USD-normalized revenue versus $4.0M for TRDA. In operating R&D and SG&A reinvestment, AURA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TRDA.
TRDA screens cheaper on headline valuation multiples. AURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas TRDA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 50.5x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AURA (-61.7% ROE) versus TRDA (-59.9% ROE) capital efficiency.
In options market volatility and institutional positioning, AURA carries 160.1% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 75% Vol realized risk). By comparison, TRDA carries 317.8% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.66β · 114% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.